Chiral Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.35 M
- Company Age 29 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.05 M
- Revenue Growth -5.43%
- Profit Growth -79.77%
- Ebitda -9.04%
- Net Worth 15.04%
- Total Assets -25.20%
About Chiral Drugs
Chiral Drugs Pvt Ltd (CDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 19 October 1995 and has a history of 29 years and four months. Its registered office is in Surat, Gujarat, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.35 M.
The company has closed loans amounting to ₹6.05 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Dhansukhbhai Golakiya and Paresh Donda serve as directors at the Company.
Company Details
- Location
Surat, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ1995PTC027929
- Company No.
027929
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Chiral Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhansukhbhai Golakiya  | Director | 25-Sep-2018 | Current |
| Paresh Donda | Director | 19-Oct-1995 | Current |
Financial Performance of Chiral Drugs.
Chiral Drugs Pvt Ltd, for the financial year ended 2022, experienced Minor drop in revenue, with a 5.43% decrease. The company also saw a substantial fall in profitability, with a 79.77% decrease in profit. The company's net worth Soared by an impressive increase of 15.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chiral Drugs?
In 2022, Chiral Drugs had a public holding of 25.07%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹6.05 M
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.61 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Mar 1998 | Bank Of Baroda | ₹6.05 M | Satisfied |
How Many Employees Work at Chiral Drugs?
Chiral Drugs has a workforce of 22 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chiral Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chiral Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
